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Abstract
Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In
addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical
development are being developed and are rapidly migrating to clinical application. One area of active development
is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class
tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
Precision therapy with targeted agents against tyrosine
kinases and cancer-associated molecules has been lead-
ing the revolution of cancer treatment [1–7]. Cancer im-
munotherapy represents another wave of revolution in
cancer therapy [8–13]. In addition to monoclonal anti-
bodies against CD20 and CD30 [14, 15], the main agents
of immunotherapeutics in clinical development include
the following : (1) immunomodulators (e.g., lenalidomide)
[16]; (2) immune checkpoint blockers (e.g., pembrolizu-
mab, nivolumab, ipilumumab) [10, 11, 17]; (3) T cell acti-
vators (e.g., CAR-T19; blinatumomab, AFM11) [18–20];
(4) inhibitors of B cell receptor signaling (e.g., ibrutinib)
[2, 21]; and (5) NK cell activators (e.g., AFM13) [22].
AFM13 is a first-in-class tetravalent bispecific anti-CD30/
CD16A antibody for NK cell-mediated immunotherapy.
NK cell-activating bispecific antibody (bsAb)
CD16 (FcγRIII) is a low-affinity receptor for the IgG Fc
domain and has two isoforms, CD16A and CD16B [23].
CD16A is an activating receptor mainly expressed on NK
cells and macrophages. CD16B is expressed mainly on
granulocytes and is not involved in tumor cell killing [23].
CD30 is expressed mainly by the Hodgkin and Reed-
Sternberg cells in patients with Hodgkin’s lymphoma
(HL). A bispecific antibody against CD30/CD16, HRS-
3/A9, was reported to bind to the CD30 antigen with
one arm, whereas the other arm binds to the CD16
antigen [24]. This HRS-3/A9 bsAb was shown to re-
cruit and activate NK cells and induce complete remis-
sion of CD30+ tumors [24]. Phase I/II studies were
done in 15 patients with refractory HL [25, 26]. HRS-3/
A9 was infused every 3 to 4 days for a total of 4 times,
starting with 1 mg/m2. The maximum tolerated dose
(MTD) was not reached at 64 mg/m2, the highest dose ad-
ministered, because of the limited availability of HRS-3/
A9. Nine of the 15 patients developed human anti-mouse
Ig antibodies. Four of the patients had an allergic reaction
on retreatment. One complete remission (CR) and one
partial remission (PR) were seen. These studies led to the
further development of NK-activating bsAbs.
AFM13
AFM13 is a tetravalent bsAb against CD30 and CD16A
produced from the mammalian CHO cells by Reusch et
al. [27]. Initially, a human anti-CD16A antibody with no
binding to 16B isoform was isolated. The variable anti-
CD16A-specific human scFv was then derived. The anti-
CD30 Fv domain was derived from the murine HRS-3
IgG. The heavy and light chain DNA sequences of CD30
and CD16A were then molecularly engineered in a spe-
cial order (Fig. 1) [27]. The CD30 and CD16A peptide
domains were linked by a 9-amino acid linker peptide to
form a bispecific diabody [28]. A tandem diabody with
four domains was engineered to form a single
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polypeptide (nonfunctional monomer) (Fig. 2). A fully
functional tetravalent bispecific chimeric antibody con-
struct (TandAb) is formed by homodimerization of the
single polypeptide monomer through non-covalent in-
teractions of the domains in the Ig heavy (VH) and light
(VL) variable chains. The TandAb has a molecular weight
of 104 kDa. One arm of AFM13 binds to the CD30 anti-
gen on lymphoma cells, whereas the other arm binds to
the CD16A antigen on the NK cells (Fig. 3). The anti-
CD30/CD16A tetravalent bsAb AFM13 was shown to
have an IC50 value of 35.8 nM for CD30 antigen. Cyto-
toxicity assays showed that the AFM13-mediated activa-
tion of NK cells was strictly CD30-dependent. In the
absence of CD30 target cells, neither cytotoxicity nor
NK cell activation was elicited by the TandAb [27].
AFM13 was studied by the groups in Germany and
in MD Anderson Cancer Center in a phase I dose-
escalation study in 28 patients who have been heavily
pretreated for their relapsed/refractory CD30+ HL
(AFM13-101, NCT01221571) [22]. AFM13 was in-
fused weekly for 4 weeks as one cycle at doses ranged
between 0.01 and 7 mg/kg body weight. The MTD was
not reached. The only dose-limiting toxicity reported
in the study was hemolytic anemia in a patient who re-
ceived 3 infusions at 0.5 mg/kg. Significant NK cell ac-
tivation and reduction of soluble CD30 in peripheral
blood were reported, though the best clinical response
was only PR (11.5 %, 3/26 evaluable patients). In pa-
tients who received AFM13 at a dose of ≥1.5 mg/kg,
the overall response rate was 23 % and the overall dis-
ease control rate was 77 % in the heavily pretreated
subjects. Brentuximab vedotin (BV) is an antibody-
drug conjugate which also binds to CD30 and delivers
a chemotherapeutic agent to the CD30+ cells [15]. In
this study, AFM13 was found to be active in BV-
refractory patients. Since the effector mechanism of
Fig. 1 Gene structure of tetravalent bispecific AFM13 antibody domains. The heavy and light chain DNA sequences of CD30 and CD16A were
molecularly engineered in the special order as shown. This figure was modified from Rothe et al. and Reusch et al. [22,27]
Fig. 2 Protein structure and antibody formation pathway of the tetravalent bispecific AFM13 antibody. The CD16A (domain A, diamond shape) and
CD30 (domain B, oval shape) peptide domains were linked by a 9-amino acid linker (L) to form a single polypeptide (nonfunctional monomer). A fully
functional tetravalent bispecific chimeric antibody construct (TandAb) is formed by homodimerization of the single polypeptide monomer in a
head-to-tail fashion through non-covalent interactions (dotted lines) of the domains in the Ig heavy (VH) and light (VL) variable chains. The AFM13
TandAb has a molecular weight of approximately 104 kDa. This figure was modified from Rothe et al. and Reusch et al. [22, 27]
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these two antibodies is entirely different, AFM13 rep-
resents a novel agent for HL refractory to BV.
Issues and future directions
AFM13 is a chimeric antibody with a murine anti-CD30
domain. Antidrug antibodies (ADA) were detected in 15
out of 28 patients. Half of the detected ADAs had neu-
tralizing potential. This remains an issue for further in-
vestigation in a large cohort. The half-life of AFM13 was
19 h, which is longer than that of the smaller bispecific
BiTE antibody, blinatumomab, which is administered as
a continuous infusion [19, 29]. Dosage, dosing-schedules,
such as twice-weekly dosing, and duration of treatment
are the issues for further investigations. Future studies
are also needed for correlation of clinical activity with
biomarkers, such as NK cell numbers, and soluble
CD30 molecules. Evaluation of these biomarkers in the
biopsy specimens will also be informative. A phase II
study is underway for this novel tetravalent bsAb
AFM13 as the first-in-class NK cell-specific agent for
cellular immunotherapy targeting CD30+ malignancies
(GHSG-AFM13, NCT02321592). Additional tetravalent
bsAbs are also being engineered for targeting other ma-
lignancies [20, 30].
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